Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f66348c0bd049194beed66aa16d2623d |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 |
filingDate |
2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dfdbfae9ad20fbbbaa1800c8b6d1572 |
publicationDate |
2018-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3269375-A1 |
titleOfInvention |
Cancer medication |
abstract |
A cancer drug is formed by a pyrimidine base having N-1 glycosidically linked glucose or gluconic acid, the pyrimidine base being substituted in its 5-position with a furfural group. |
priorityDate |
2016-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |